Why is Alkermes stock sliding today? By Investing.com
Alkermes (ALKS) shares fell 5.2% pre-market to $50 after Q2 2026 results. Adjusted EPS was $0.00 vs -$0.02 expected, and revenue rose to $496M vs $459M forecast. Full-year 2026 revenue guidance midpoint was $1.785B vs $1.81B consensus. Piper Sandler raised its price target to $65 from $43.
How this was made
The 30-second read
Why it matters
Investors appear to be repricing the stock based on the full-year 2026 revenue guidance midpoint coming in below consensus, turning a beat into a near-term headwind.
Market read
The actionable takeaway is the guidance midpoint shortfall versus consensus, which is driving the immediate sell-off and may influence near-term positioning given prior YTD strength and short interest.
What to watch
Short interest (~10.7% of float) and a crowded long position may exaggerate the move; integration costs from the Avadel deal could be temporary rather than structural.
Background
Alkermes’ Q2 2026 print included a revenue beat and EPS beat, with LUMRYZ franchise contribution following the earlier Avadel acquisition.
Ticker impact
Alkermes shares fell 5.2% pre-open after Q2 results beat EPS and revenue, but the full-year 2026 revenue guidance midpoint missed consensus.
Near-term pressure likely persists until investors digest the guidance gap and any follow-up commentary on integration costs and LUMRYZ ramp.
The article cites a below-consensus guidance midpoint ($1.785B vs $1.81B) as the catalyst for the sell-off, alongside elevated YTD gains and short interest that can amplify profit-taking.
Market effects
Could modestly affect sentiment toward specialty pharma/narcolepsy franchise names if investors generalize guidance conservatism.
Limited evidence of broad index-driven selling; article frames weakness as company-specific.
Primarily US-focused read-through via Nasdaq/S&P context; no direct global catalyst cited.
Counterpoint
The revenue and EPS beat plus a raised Piper Sandler price target ($65) could mean the guidance miss is more about conservatism than deteriorating fundamentals.
Key entities
- companyAlkermes
Subject of the article; pre-open shares down 5.2% after Q2 results and guidance midpoint miss.
- product_franchiseLUMRYZ
Narcolepsy-focused franchise cited as contributing to the revenue beat, but integration costs and tempered outlook weigh on sentiment.
- companyAvadel Pharmaceuticals
Acquisition of Avadel completed earlier this year, linked to LUMRYZ contribution and integration-cost concerns.
- analyst_firmPiper Sandler
Raised price target to $65 from $43 and maintained Overweight, offering a supportive counterpoint.
